An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

Phase 1b–2 trial evaluates the potential of CAR T-cell therapy obe-cel in relapsed or refractory B-cell ALL patients. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in inducing ...

The FDA approved Blincyto for patients aged one month and older with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. The Food and Drug Administration ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

—The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at diagnosis were associated with worse ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

CAR7, has shown remarkable success in reversing an aggressive form of leukemia. This world-first treatment uses genetically reprogrammed donor T-cells to target and destroy cancerous cells, offering ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. This story was originally published on BioPharma Dive. To receive daily news ...